Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices
复制标题
DOI：
10.6004/jnccn.2015.0166
复制
发表时间：
2015-11-01
影响因子：
13.4
通讯作者：
Lyman, Gary H.
中科院分区：
文献类型：
--
作者：
Denduluri, Neelima;Patt, Debra A.;Lyman, Gary H.
背景：在临床实践中，多种骨髓抑制化疗方案被用于治疗癌症。中性粒细胞减少的并发症，如发烧的中性粒细胞减少，是化疗最常见的副作用之一，它们通常需要推迟或减少骨髓抑制药物的剂量。降低相对剂量强度(RDI)可能会导致更差的无病生存和总体生存。方法：利用McKesson Specialty Health/US Oncology iKnowMed电子健康记录数据库，我们回顾了2007年1月1日至2011年3月31日期间开始治疗的无转移患者接受辅助或新辅助化疗的第一个疗程。对于每个方案，我们估计了剂量延迟(在疗程的任何周期中=7天)、剂量减少(在疗程的任何周期=15%)和RDI降低(
Background: A wide variety of myelosuppressive chemotherapy regimens are used for the treatment of cancer in clinical practice. Neutropenic complications, such as febrile neutropenia, are among the most common side effects of chemotherapy, and they often necessitate delays or reductions in doses of myelosuppressive agents. Reduced relative dose intensity (RDI) may lead to poorer disease-free and overall survival. Methods: Using the McKesson Specialty Health/ US Oncology iKnowMed electronic health record database, we retrospectively identified the first course of adjuvant or neoadjuvant chemotherapy received by patients without metastases who initiated treatment between January 1, 2007, and March 31, 2011. For each regimen, we estimated the incidences of dose delays (>= 7 days in any cycle of the course), dose reductions (>= 15% in any cycle of the course), and reduced RDI (